title: [The specific cox-2 inhibitor valdecoxib provides effective analgesia after inguinal hernia surgery].
abstract: OBJECTIVE
  To compare 3 oral analgesic doses--valdecoxib 20 mg, valdecoxib 40 mg and controlled-release diclofenac 75 mg--to placebo in the treatment of pain after inguinal herniorrhaphy.
  
  
  METHODS
  An international multicenter double-blind placebo-controlled trial comparing parallel groups receiving oral valdecoxib 20 or 40 mg, controlled-release diclofenac 75 mg, or placebo every 12 hours over a period of 36 hours. The study enrolled 269 patients undergoing inguinal herniorrhaphy with spinal anesthesia. Pain intensity difference, the sum pain intensity difference, need for rescue medication, and overall patient satisfaction were compared.
  
  
  RESULTS
  Valdecoxib 40 mg and controlled-release diclofenac 75 mg take every 12 hours provided similar analgesia that was significantly more efficacious than placebo as shown by the sum pain intensity difference at 12 hours. Both treatments decreased pain intensity in comparison with baseline throughout the study. Differences were significant in comparison with placebo at 8-10 hours through 24 hours of administration of the first dose. No significant differences between valdecoxib 20 mg and placebo were observed. The percentage of patients needing rescue medication was significantly lower in the valdecoxib 40 mg group (30% in that group vs. 52% for placebo), and that difference was not seen for any of the other groups. All treatments were well tolerated.
  
  
  CONCLUSIONS
  Valdecoxib 40 mg and diclofenac 75 mg provided similar quality of analgesia for treating pain after inguinal herniorrhaphy.
authors.affiliation: Servicio de Anestesiología, Reanimación y Unidad del Dolor. Hospital Universitario Puerta del Mar. Cádiz. luismtorres@arrakis.es
authors.forename: L M
authors.initials: LM
authors.lastname: Torres
authors.forename: J
authors.initials: J
authors.lastname: Cabrera
authors.forename: J
authors.initials: J
authors.lastname: Martínez
authors.forename: E
authors.initials: E
authors.lastname: Calderón
authors.forename: S
authors.initials: S
authors.lastname: Fernández
authors.forename: J
authors.initials: J
authors.lastname: Chaves
mesh_terms: D000698:Analgesia; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D004008:Diclofenac; D004311:Double-Blind Method; D005260:Female; D006552:Hernia, Inguinal / Q000601:surgery*; D006801:Humans; D007555:Isoxazoles; D008297:Male; D008565:Membrane Proteins; D008875:Middle Aged; D010149:Postoperative Pain / Q000209:etiology / Q000517:prevention & control*; D011451:Prostaglandin-Endoperoxide Synthases; D013449:Sulfonamides; D000096926:Benzenesulfonamides
chemical_list: D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D004008:Diclofenac; D007555:Isoxazoles; D008565:Membrane Proteins; D011451:Prostaglandin-Endoperoxide Synthases; D013449:Sulfonamides; C406224:valdecoxib; D000096926:Benzenesulfonamides; C496540:PTGS2 protein, human